Stockscreener 앱 받기
99.29
1.20%
1.18
시간 외 거래:
100.00
0.71
+0.72%
전일 마감가:
$98.11
열려 있는:
$97.44
하루 거래량:
1.49M
Relative Volume:
0.46
시가총액:
$19.68B
수익:
$742.00K
순이익/손실:
$-1.13B
주가수익비율:
-16.78
EPS:
-5.9165
순현금흐름:
$-913.73M
1주 성능:
+4.44%
1개월 성능:
-3.36%
6개월 성능:
+128.04%
1년 성능:
+156.23%
1일 변동 폭
$97.42
$100.08
1주일 범위
$94.67
$100.51
52주 변동 폭
$29.17
$124.49
Revolution Medicines Inc Stock (RVMD) Company Profile
명칭
Revolution Medicines Inc
전화
650-481-6801
주소
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
99.29 | 19.44B | 742.00K | -1.13B | -913.73M | -5.9165 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-02-27 | 재개 | UBS | Buy |
| 2025-11-18 | 개시 | Wolfe Research | Outperform |
| 2025-11-03 | 개시 | RBC Capital Mkts | Outperform |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-10-16 | 재개 | Stifel | Buy |
| 2025-09-12 | 재개 | Raymond James | Strong Buy |
| 2025-09-05 | 개시 | Truist | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-08-15 | 개시 | Wells Fargo | Overweight |
| 2025-07-15 | 개시 | Goldman | Buy |
| 2024-07-16 | 재확인 | Needham | Buy |
| 2024-07-12 | 개시 | Barclays | Overweight |
| 2024-07-08 | 개시 | Jefferies | Buy |
| 2024-04-12 | 재확인 | Needham | Buy |
| 2024-04-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-01-04 | 개시 | Wedbush | Outperform |
| 2023-11-16 | 개시 | Raymond James | Outperform |
| 2023-02-28 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-10-21 | 개시 | Oppenheimer | Outperform |
| 2022-05-20 | 개시 | BofA Securities | Neutral |
| 2022-03-01 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-08-12 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-05-18 | 개시 | Goldman | Buy |
| 2020-05-21 | 개시 | H.C. Wainwright | Buy |
| 2020-03-09 | 개시 | Cowen | Outperform |
| 2020-03-09 | 개시 | Guggenheim | Buy |
| 2020-03-09 | 개시 | JP Morgan | Neutral |
모두보기
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
Revolution Medicines (RVMD) Among Top Biotech M&A Targets - GuruFocus
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. - The Motley Fool
RBC names top M&A candidates in biotech (RVMD:NASDAQ) - Seeking Alpha
Revolution Medicines, Inc. (RVMD) net loss widens amid progress on clinical trial programs - MSN
Piper Sandler Initiates Coverage of Revolution Medicines (RVMD) with an Overweight Rating - MSN
Stifel Reiterates Revolution Medicines (RVMD) Buy Recommendation - MSN
Wells Fargo Initiates Coverage of Revolution Medicines (RVMD) with Overweight Recommendation - MSN
Revolution Medicines Secures $2 Billion Flexible Financing Deal with Royalty Pharma - MSN
Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting - Bitget
Revolution Medicines Showcases RAS(ON) Inhibitor Pipeline Advances at AACR Annual Meeting 2026 - Quiver Quantitative
Revolution Medicines to Showcase Progress Across RAS(ON) - GlobeNewswire
Revolution Medicines brings lung and pancreatic cancer trial data to AACR 2026 - Stock Titan
Algert Global LLC Boosts Position in Revolution Medicines, Inc. $RVMD - MarketBeat
RVMD: Jefferies Raises Price Target for Revolution Medicines to $140 | RVMD Stock News - GuruFocus
RVMD SEC FilingsRevolution Medicines, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Revolution Medicines (NASDAQ:RVMD) Now Covered by Analysts at Jefferies Financial Group - MarketBeat
Revolution Medicines, Inc. $RVMD Shares Acquired by HighVista Strategies LLC - MarketBeat
Holocene Advisors LP Sells 195,669 Shares of Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines, Inc. $RVMD is Farallon Capital Management LLC's 6th Largest Position - MarketBeat
Decheng Capital LLC Reduces Stock Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines, Inc. $RVMD is Boxer Capital Management LLC's 3rd Largest Position - MarketBeat
Casdin Capital LLC Cuts Stake in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines, Inc. $RVMD Shares Bought by Checkpoint Capital L.P. - MarketBeat
Revolution Medicines, Inc. $RVMD Shares Acquired by Baker BROS. Advisors LP - MarketBeat
Integral Health Asset Management LLC Has $18.68 Million Stock Holdings in Revolution Medicines, Inc. $RVMD - MarketBeat
General Atlantic L.P. Acquires New Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Director files Form 144 to sell RVMD shares (NASDAQ: RVMD) - Stock Titan
ETRADE (RVMD) Form 144 lists RSU grants and prospective resale activity - Stock Titan
Stephen Kelsey sold 5,447 shares — Revolution Medicines (NASDAQ: RVMD) - Stock Titan
Margaret Horn sells 75,000 shares (NASDAQ: RVMD) in Form 144 filing - Stock Titan
Mark Goldsmith sells shares at Revolution Medicines (NASDAQ: RVMD) - Stock Titan
Insider sales reported at Revolution Medicines (NASDAQ: RVMD) — specific proceeds disclosed - Stock Titan
[144] Revolution Medicines, Inc. SEC Filing - Stock Titan
RVMD Stock Price, Quote & Chart | REVOLUTION MEDICINES INC (NASDAQ:RVMD) - ChartMill
Victory Capital Management Inc. Trims Stock Holdings in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines (RVMD) price target increased by 10.10% to 92.82 - MSN
A Look At Revolution Medicines (RVMD) Valuation After Recent Share Price Momentum - Yahoo Finance
Revolution Medicines’ Daraxonrasib Granted FDA Breakthrough Therapy Designation for Pancreatic Cancer with KRAS G12 Mutations - MSN
Revolution Medicines gets FDA Breakthrough Therapy status for daraxonrasib - MSN
Why Revolution Medicines Inc. Equity Warrant stock is trending among retail tradersJuly 2025 Macro Moves & Daily Stock Momentum Reports - Naître et grandir
Revolution Medicines (RVMD) director Elizabeth Anderson gifts 30,000 shares - Stock Titan
Earnings Report: Is Revolution Medicines Inc affected by consumer sentimentEarnings Recap Summary & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
This One Data Readout Could Make Or Break Revolution Medicines (NASDAQ:RVMD) - Seeking Alpha
Is Revolution Medicines (RVMD) Pricing Fully Reflect Its Surging Oncology Pipeline Potential - simplywall.st
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights - Yahoo Finance
Handelsbanken Fonder AB Grows Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines Insider Sold Shares Worth $3,644,354, According to a Recent SEC Filing - marketscreener.com
Revolution Medicines (NASDAQ:RVMD) Insider Mark Goldsmith Sells 30,000 Shares - MarketBeat
Revolution Medicines director Goldsmith sells shares worth $3.64 million - Investing.com Australia
Equity awards increase Wei Lin’s stake in Revolution Medicines (RVMD) - Stock Titan
Revolution Medicines (RVMD) grants CFO new stock and option awards - Stock Titan
Revolution Medicines Inc (RVMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
0.06%
자본화:
|
볼륨(24시간):